Results 241 to 250 of about 406,416 (358)

The plant-specific cyclin-dependent kinase CDKB1;1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis [PDF]

, 2004
Boudolf, Véronique, Vlieghe, Kobe, Beemster, Gerrit, Magyar, Zoltán, Torres Acosta, Juan Antonio, Maes, Sara, Van Der Schueren, Els, Inzé, Dirk, De Veylder, Lieven   +8 more
core   +2 more sources

GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors. [PDF]

Biol Open
Luca E, Shapiro I, Debaix H, Zitzmann K, Wang K, Auernhammer CJ, Beuschlein F, Nölting S, Hantel C.   +8 more
europepmc   +1 more source

The role of cyclin dependent kinase 2 (Cdk2) in the proliferation and differentiation of pluripotent embryonic stem cells / Elaine B. Stead.

, 2002
Elaine Stead
openalex   +1 more source

Caffeic acid suppresses cyclin D1 expression by directly binding to ribosomal protein S5 in colorectal cancer cells. [PDF]

Sci Rep
Watanabe M, Boku S, Sukeno M, Kobayashi K, Kameda T, Iizumi Y, Nishio W, Mutoh M, Sakai T.   +8 more
europepmc   +1 more source

CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia [PDF]

, 2016
De Belleroche, JS
core   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Erratum: [Corrigendum] Effects of 17-allylamino-17-demethoxygeldanamycin on the induction of apoptosis and cell cycle arrest in HCT-116 cells. [PDF]

Oncol Lett
Zhao X, Wang J, Xiao L, Xu Q, Zhao E, Zheng X, Zheng H, Zhao S, Ding S.   +8 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy. [PDF]

Front Oncol
Cui M, Xiao J, Ma L, Liang Y, Liang J.
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source